Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Armstrong, Paul; Pieske, Burkert; Anstrom, Kevin; Ezekowitz, Justin; Hernandez, Adrian; Butler, Javed; Lam, Carolyn; Ponikowski, Piotr; Voors, Adriaan; Jia, Gang; McNulty, Steven; Patel, Mahesh; Roessig, Lothar; Koglin, Joerg; O'Connor, Christopher

doi:10.1056/nejmoa1915928

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Copy For Citation

Armstrong P. W., Pieske B., Anstrom K. J., Ezekowitz J., Hernandez A. F., Butler J., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.382, no.20, pp.1883-1893, 2020 (SCI-Expanded)

Publication Type: Article / Article
Volume: 382 Issue: 20
Publication Date: 2020
Doi Number: 10.1056/nejmoa1915928
Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
Page Numbers: pp.1883-1893
Dokuz Eylül University Affiliated: No

Abstract

BackgroundThe effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.